JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beauchamp, H. T.
Right arrow Articles by Gibson, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beauchamp, H. T.
Right arrow Articles by Gibson, R. E.

In vivo receptor occupancy of the angiotensin II receptor by nonpeptide antagonists: relationship to in vitro affinities and in vivo pharmacologic potency

HT Beauchamp, RS Chang, PK Siegl and RE Gibson

Department of Pharmacology, Merck Research Laboratories, West Point, Pennsylvania.

The affinities of 13 angiotensin II antagonists for the AT1 subtype determined in vitro with tissue homogenates were shown not to correlate well with in vivo pharmacologic potency. The addition of human serum albumin to the in vitro assay to mimic in vivo plasma protein interactions reduced the measured affinity by reducing the effective free concentrations of antagonists, but the resulting affinities were not predictive of the in vivo effects. Using an in vivo radioligand competition assay, in which receptor occupancy is demonstrated via competitive blockade of the in vivo binding of [125I][Sar1,Ile8]angiotensin II to AT1 receptors in rat kidney cortex, we demonstrated that the in vivo pharmacologic potencies reflect receptor occupancy. By comparing the effects of rat plasma and bovine serum albumin on the in vitro affinity of two antagonists, we suggest that the use of plasma would alter free plasma concentrations in a manner more consistent with in vivo measures of potencies.

Volume 272, Issue 2, pp. 612-618, 02/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
T. Oki, A. Toma-Okura, and S. Yamada
Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion
J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1137 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Yamada, T. Okura, and R. Kimura
In Vivo Demonstration of {alpha}1A-Adrenoceptor Subtype Selectivity of KMD-3213 in Rat Tissues
J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 160 - 167.
[Abstract] [Full Text]

Home page
 J. Pharmacol. Exp. Ther.Home page
S. Yamada, T. Ohkura, Y. Deguchi, and R. Kimura
In Vivo Measurement by [3H]Tamsulosin of alpha 1 Adrenoceptors in Rat Tissues in Relation to the Pharmacokinetics
J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1575 - 1583.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1995 by the American Society for Pharmacology and Experimental Therapeutics.